Results 61 to 70 of about 20,060 (180)

Acute pancreatitis associated with boceprevir: a case report

Brazilian Journal of Infectious Diseases, 2014
Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30–50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy,
Juliana Miguel Bilar, Roberto José Carvalho-Filho, Carolina Frade Magalhães Girardin Pimentel Mota, Patricia da Silva Fucuta, Maria Lucia Cardoso Gomes Ferraz   +4 more
doaj   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4

Annals of Hepatology, 2013
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferon plus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have
Juan José Urquijo, Moisés Diago, M.D., Jaume Boadas, Ramón Planas, Ricard Solá, Juan Angel del Olmo, Javier Crespo, José Carlos Erdozaín, María Dolores Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Josep M Barrera, Javier Gracia-Samaniego, Ricardo Perez, Blai Dalmau, Miguel Montoro   +16 more
doaj   +1 more source

Nanomaterial‐Mediated Near‐Infrared Photothermal Neuromodulation for Neurologic Disorders

Advanced NanoBiomed Research, Volume 6, Issue 5, May 2026.
This review summarizes how near‐infrared light activates photothermal nanomaterials to enable noninvasive neuromodulation with high spatiotemporal precision. It elucidates the underlying mechanisms, explores targeted therapeutic applications for neurological disorders, discusses integration with optogenetics and biosensors, and addresses future ...
Ting‐Ting Zeng, Yu‐Ge Wang, Ya‐Bing Zhang, Yuan‐Xin Bai, Si‐Tong Lin, Ting‐Ting Zhu, Yan‐Bo Zhou, Wei‐Tong Pan, Pan‐Miao Liu, Jian‐Jun Yang   +9 more
wiley   +1 more source

The Expanding Role of Companion Diagnostics in Infectious Diseases: Lessons From Abacavir and Human Immunodeficiency Virus Care

iLABMED, EarlyView.
Yi‐Wei Tang, Eric von Hofe
wiley   +1 more source

Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer

Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Background The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has ...
Nima Javanmehr, Asal Moazzami Ashtyani, Robabehbeygom Ghafelehbashi, Fateme Mousavi, Hossein Teimouri   +4 more
wiley   +1 more source

Hepatitis C Virus and Type 2 Diabetes: Mechanisms, Clinical Impact, and Post‐DAA Management

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Hepatitis C virus (HCV) infection remains a major global health burden despite advances in direct‐acting antiviral (DAA) therapies. Beyond hepatic complications such as cirrhosis and hepatocellular carcinoma (HCC), HCV has been strongly linked to metabolic disorders, particularly type 2 diabetes mellitus (T2DM).
Shen‐Shong Chang, Ching‐Hsuan Liu, Shu‐Yen Chan, Liang‐Tzung Lin   +3 more
wiley   +1 more source

Relapse of Vogt-Koyanagi-Harada Disease during Interferon-α and Ribavirin Therapy in a Case of Chronic Viral Hepatitis C

Case Reports in Ophthalmology, 2011
A 60-year-old woman, who had been diagnosed with and treated for Vogt-Koyanagi-Harada (VKH) disease 17 years before, was receiving pegylated interferon-α and ribavirin therapy for chronic hepatitis C virus.
Miho Soma, Akira Hirata, Takamitsu Takahashi, Satoshi Okinami   +3 more
doaj   +1 more source

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics‐Based Biomarkers

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Interindividual variability in drug pharmacokinetics and susceptibility to drug–drug interactions remain major barriers in precision dosing, particularly for narrow therapeutic index drugs. While genetic factors contribute, much variability arises from dynamic influences such as physiology, disease, age, diet, microbiome, and concomitant ...
Bhagwat Prasad
wiley   +1 more source